Skip to the page

Data / Drug companies / Laurus Labs Limited

Laurus Labs Limited: 86 products in the FDA NDC directory, labeler code 42385

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Laurus Labs Limited (labeler code 42385) lists 86 products in the FDA National Drug Code Directory, covering 21 finished drugs by generic name. By type: 51 prescription drugs, 34 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 20, 2026.

The request: Watch Laurus Labs Limited (FDA labeler code 42385): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
42385
Products in commercial distribution
86
Packages
302
Finished drugs by generic name
21
Prescription products
51
Over the counter products
0
Controlled substance products
Schedule V 1
Flagged as original packager
45 of 45 products that carry the flag
Started marketing in the last 12 months
10
Earliest marketing start
November 21, 2008
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)5159.3%
Bulk ingredients3439.5%
Drugs for further processing11.2%

Products by type

TypeProductsShare
Prescription drugs5159.3%
Bulk ingredients3439.5%
Drugs for further processing11.2%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet, film coated3338.4%
Powder3237.2%
Capsule1315.1%
Tablet44.7%
Tablet, extended release22.3%
Liquid11.2%
Granule11.2%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Ticagrelor42385-994TabletGeneric drugs (ANDA)August 20, 2026
Ticagrelor42385-993TabletGeneric drugs (ANDA)August 20, 2026
Suzetrigine42385-617Tablet, film coatedDrugs for further processingJuly 28, 2026
Rilpivirine42385-999Tablet, film coatedGeneric drugs (ANDA)July 10, 2026
Macitentan42385-907Tablet, film coatedGeneric drugs (ANDA)May 15, 2026
Valsartan42385-992Tablet, film coatedGeneric drugs (ANDA)April 22, 2026
Valsartan42385-991Tablet, film coatedGeneric drugs (ANDA)April 22, 2026
Valsartan42385-990Tablet, film coatedGeneric drugs (ANDA)April 22, 2026
Valsartan42385-989Tablet, film coatedGeneric drugs (ANDA)April 22, 2026
Emtricitabine, rilpivirine and tenofovir disoproxil fumarate42385-801Tablet, film coatedGeneric drugs (ANDA)March 5, 2026
Flucytosine42385-984CapsuleGeneric drugs (ANDA)July 24, 2025
Flucytosine42385-983CapsuleGeneric drugs (ANDA)July 24, 2025
Sacubitril and Valsartan42385-932Tablet, film coatedGeneric drugs (ANDA)November 11, 2024
Sacubitril and Valsartan42385-931Tablet, film coatedGeneric drugs (ANDA)November 11, 2024
Sacubitril and Valsartan42385-930Tablet, film coatedGeneric drugs (ANDA)November 11, 2024
Oseltamivir42385-987CapsuleGeneric drugs (ANDA)May 2, 2024
Oseltamivir42385-986CapsuleGeneric drugs (ANDA)May 2, 2024
Oseltamivir42385-985CapsuleGeneric drugs (ANDA)May 2, 2024
Gabapentin42385-980Tablet, film coatedGeneric drugs (ANDA)April 9, 2024
Gabapentin42385-979Tablet, film coatedGeneric drugs (ANDA)April 9, 2024
Atorvastatin Calcium42385-943Tablet, film coatedGeneric drugs (ANDA)January 23, 2024
Atorvastatin Calcium42385-942Tablet, film coatedGeneric drugs (ANDA)January 23, 2024
Atorvastatin Calcium42385-941Tablet, film coatedGeneric drugs (ANDA)January 23, 2024
Atorvastatin Calcium42385-940Tablet, film coatedGeneric drugs (ANDA)January 23, 2024
Metformin hydrochloride42385-978Tablet, extended releaseGeneric drugs (ANDA)October 6, 2023

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.